The Asia Pacific Wearable Injectors Market is expected to witness market growth of 9.8% CAGR during the forecast period (2022-2028).
Wearable injectors that may work in combination with other devices, as well as technologies, are easy to popularize in the presence of numerous new technologies that have been introduced to the forefront of the healthcare sector. The delivery system is a vital part of the treatment process because it ensures that medication doses are administered on time. Given these facts, it is reasonable to anticipate that the wearable injectors market is expected to continue to grow in the coming years.
Wearable injection systems are the natural development of chronic disorder management in a world that needs everything to happen immediately. The concept of patient-centricity and greater attention to human factors in drug delivery design has fueled the development of these devices. The growing use of biologics in drug research has aided the development of delivery systems capable of handling high-viscosity solutions. As a result of these circumstances, wearable injection systems have emerged, offering a whole new set of design and testing issues.
Device manufacturers face a unique design problem with this component. Adhesives are not a compound present in many traditional drug-delivery devices, necessitating the development of new skills and knowledge. The adhesive characteristics of the product must be optimized for patient comfort during usage and removal, and the adhesive patch must be developed in such a way that proper orientation, as well as skin contact, are maintained throughout the delivery process.
Infectious illness threats can be swiftly prevented, detected, and responded to in countries with robust and resilient public health systems before they become pandemic. According to the Centers for Disease Control and Prevention, China's ecology provides a risk for developing, re-emerging, and novel illnesses that could threaten China, along with other regional countries, with a population of over 1.4 billion people and 50% of the world's livestock. The world's expanding network of air travel routes greatly raises the chance of illnesses spreading quickly, including infections that could lead to pandemics like COVID-19, causing worldwide trade disruption, illness, or death. The CDC encourages China to build effective procedures for addressing disease outbreaks at their cause. CDC along with the China Center for Disease Control, also known as China CDC, have partnered in supporting global public health activities as China's domestic public health capability has increased. In addition, the CDC works with China's CDC to promote the one health approach, which recognizes that human health is linked to animal and environmental health. This strategy tries to lessen the burden of brucellosis, rabies, and other zoonotic illnesses on humans.
The China market dominated the Asia Pacific Wearable Injectors Market by Country 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $981.9 Million by 2028. The Japan market is poised to grow at a CAGR of 9.1% during (2022 - 2028). Additionally, The India market is expected to witness a CAGR of 10.5% during (2022 - 2028).
Based on Therapy, the market is segmented into Diabetes, Cardiovascular disease, Immuno-oncology, and Others. Based on End User, the market is segmented into Hospitals & Clinics and Home healthcare setting. Based on Type, the market is segmented into On-body Injector and Off-body Injector. Based on Technology, the market is segmented into Spring Based, Motor Based, Rotary pump, Expanding battery, and other. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Insulet Corporation, United Therapeutics Corporation, ATS Automation Tooling Systems, Inc., Ypsomed AG, Amgen, Inc., West Pharmaceutical Services, Inc., Zealand Pharma A/S (Valeritas, Inc.), Medtronic PLC, CeQur SA, and Subcuject ApS.
Wearable injectors that may work in combination with other devices, as well as technologies, are easy to popularize in the presence of numerous new technologies that have been introduced to the forefront of the healthcare sector. The delivery system is a vital part of the treatment process because it ensures that medication doses are administered on time. Given these facts, it is reasonable to anticipate that the wearable injectors market is expected to continue to grow in the coming years.
Wearable injection systems are the natural development of chronic disorder management in a world that needs everything to happen immediately. The concept of patient-centricity and greater attention to human factors in drug delivery design has fueled the development of these devices. The growing use of biologics in drug research has aided the development of delivery systems capable of handling high-viscosity solutions. As a result of these circumstances, wearable injection systems have emerged, offering a whole new set of design and testing issues.
Device manufacturers face a unique design problem with this component. Adhesives are not a compound present in many traditional drug-delivery devices, necessitating the development of new skills and knowledge. The adhesive characteristics of the product must be optimized for patient comfort during usage and removal, and the adhesive patch must be developed in such a way that proper orientation, as well as skin contact, are maintained throughout the delivery process.
Infectious illness threats can be swiftly prevented, detected, and responded to in countries with robust and resilient public health systems before they become pandemic. According to the Centers for Disease Control and Prevention, China's ecology provides a risk for developing, re-emerging, and novel illnesses that could threaten China, along with other regional countries, with a population of over 1.4 billion people and 50% of the world's livestock. The world's expanding network of air travel routes greatly raises the chance of illnesses spreading quickly, including infections that could lead to pandemics like COVID-19, causing worldwide trade disruption, illness, or death. The CDC encourages China to build effective procedures for addressing disease outbreaks at their cause. CDC along with the China Center for Disease Control, also known as China CDC, have partnered in supporting global public health activities as China's domestic public health capability has increased. In addition, the CDC works with China's CDC to promote the one health approach, which recognizes that human health is linked to animal and environmental health. This strategy tries to lessen the burden of brucellosis, rabies, and other zoonotic illnesses on humans.
The China market dominated the Asia Pacific Wearable Injectors Market by Country 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $981.9 Million by 2028. The Japan market is poised to grow at a CAGR of 9.1% during (2022 - 2028). Additionally, The India market is expected to witness a CAGR of 10.5% during (2022 - 2028).
Based on Therapy, the market is segmented into Diabetes, Cardiovascular disease, Immuno-oncology, and Others. Based on End User, the market is segmented into Hospitals & Clinics and Home healthcare setting. Based on Type, the market is segmented into On-body Injector and Off-body Injector. Based on Technology, the market is segmented into Spring Based, Motor Based, Rotary pump, Expanding battery, and other. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Insulet Corporation, United Therapeutics Corporation, ATS Automation Tooling Systems, Inc., Ypsomed AG, Amgen, Inc., West Pharmaceutical Services, Inc., Zealand Pharma A/S (Valeritas, Inc.), Medtronic PLC, CeQur SA, and Subcuject ApS.
Scope of the Study
Market Segments Covered in the Report:
By Therapy
- Diabetes
- Cardiovascular disease
- Immuno-oncology
- Others
By End User
- Hospitals & Clinics
- Home healthcare setting
By Type
- On-body Injector
- Off-body Injector
By Technology
- Spring Based
- Motor Based
- Rotary pump
- Expanding battery
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Insulet Corporation
- United Therapeutics Corporation
- ATS Automation Tooling Systems, Inc.
- Ypsomed AG
- Amgen, Inc.
- West Pharmaceutical Services, Inc.
- Zealand Pharma A/S (Valeritas, Inc.)
- Medtronic PLC
- CeQur SA
- Subcuject ApS
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Asia Pacific Wearable Injectors Market by Therapy
Chapter 5. Asia Pacific Wearable Injectors Market by End User
Chapter 6. Asia Pacific Wearable Injectors Market by Type
Chapter 7. Asia Pacific Wearable Injectors Market by Technology
Chapter 8. Asia Pacific Wearable Injectors Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Insulet Corporation
- United Therapeutics Corporation
- ATS Automation Tooling Systems, Inc.
- Ypsomed AG
- Amgen, Inc.
- West Pharmaceutical Services, Inc.
- Zealand Pharma A/S (Valeritas, Inc.)
- Medtronic PLC
- CeQur SA
- Subcuject ApS
Methodology
LOADING...
